{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:00:25Z","timestamp":1782918025359,"version":"3.54.5"},"reference-count":30,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate quality of life (QoL) endpoints from two 12\u2010week trials investigating fremanezumab efficacy and safety in Japanese\/Korean patients with chronic (CM) or episodic (EM) migraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Migraine is a leading cause of disability and affects QoL considerably, interfering with work and daily activities, social and family life, and emotional wellbeing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This planned exploratory analysis used data from two multicenter, randomized, double\u2010blind, placebo\u2010controlled, parallel\u2010group studies in which Migraine\u2010Specific QoL (MSQoL; Role Function\u2010Restrictive [RR], Role Function\u2010Preventive [RP], and Emotional Function [EF] domains) scores and Patient Global Impression of Change (PGIC) scores were pre\u2010specified QoL outcomes in individuals receiving monthly or quarterly fremanezumab or placebo. In both trials, MSQoL was assessed at baseline, and MSQoL and PGIC at Weeks 4, 8, and 12. PGIC responders had a score of \u22655\u2009points, indicating significant improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mean baseline MSQoL scores were similar across groups in both CM (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009565; RR, 60.3\u201361.5; RP, 78.5\u201380.0; EF, 69.0\u201371.4) and EM (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009353; RR, 68.6\u201371.1; RP, 83.1\u201385.7; EF, 76.7\u201381.9) trials. In the CM trial, all three MSQoL domains improved in both fremanezumab groups at 12\u2009weeks compared with placebo: least squares mean (LSM) and standard error (SE) change from baseline,\n                      <jats:italic>p<\/jats:italic>\n                      versus placebo (quarterly; monthly; placebo): RR 14.9 (1.3),\n                      <jats:italic>p\u2009=<\/jats:italic>\n                      \u20090.030; 15.1 (1.4),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.020; 11.6 (1.3); RP 8.9 (1.1),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007; 8.6 (1.1),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.013; 5.4 (1.1); EF 13.3 (1.5),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001; 12.5 (1.5),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003; 7.5 (1.5). In the EM trial, RR\/EF domains improved in both fremanezumab groups compared with placebo: LSM change from baseline,\n                      <jats:italic>p<\/jats:italic>\n                      versus placebo (quarterly; monthly; placebo): RR 16.3 (1.4),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003; 16.4 (1.3),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002; 11.6 (1.4); EF 13.0 (1.3),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001; 11.5 (1.2),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004; 7.4 (1.3); RP improved in the quarterly group RP 8.6 (1.1),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.010; 7.6 (1.1),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.066; 5.4 (1.1). The proportion of PGIC responders at Week 12 was greater in the monthly and quarterly fremanezumab groups compared with the placebo group in the CM (96\/182 [52.7%] and 98\/180 [54.4%] vs. 68\/179 [38.0%];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05) and EM trial (81\/118 [68.6%] and 86\/113 [76.1%] vs. 38\/111 [34.2%];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with EM\/CM receiving monthly or quarterly fremanezumab, for a duration of 12\u2009weeks, showed significant improvements in their QoL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14606","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T23:22:27Z","timestamp":1692660147000},"page":"1304-1313","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Improved quality of life with fremanezumab in Japanese and Korean patients with episodic and chronic migraine: Results of two multicenter, randomized, double\u2010blind, placebo\u2010controlled, parallel\u2010group clinical trials"],"prefix":"10.1111","volume":"63","author":[{"given":"Yasuhiko","family":"Matsumori","sequence":"first","affiliation":[{"name":"Sendai Headache and Neurology Clinic  Sendai Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Ishida","sequence":"additional","affiliation":[{"name":"Headquarters of Clinical Development Otsuka Pharmaceutical Co., Ltd.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Iba","sequence":"additional","affiliation":[{"name":"Headquarters of Clinical Development Otsuka Pharmaceutical Co., Ltd.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung\u2010Kun","family":"Kim","sequence":"additional","affiliation":[{"name":"Nowon Eulji Medical Center Eulji University School of Medicine  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Ning","sequence":"additional","affiliation":[{"name":"Teva Branded Pharmaceutical Products R&amp;D, Inc.  West Chester Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5159-0432","authenticated-orcid":false,"given":"Masami","family":"Nakai","sequence":"additional","affiliation":[{"name":"Medical Affairs Otsuka Pharmaceutical Co., Ltd.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Koga","sequence":"additional","affiliation":[{"name":"Medical Affairs Otsuka Pharmaceutical Co., Ltd.  Tokushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,8,21]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01402-2"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01208-0"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14151"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-022-00387-9"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1605502"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-020-00196-2"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.pbr.2020.05.017"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2021.1995626"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0955-y"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-020-01839-5"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01393-0"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23116151"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01396-x"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14169"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14178"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419885905"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709038"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1998.3804295.x"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2011.01997.x"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14031"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2009.01852.x"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmpt.2003.11.003"},{"key":"e_1_2_13_24_1","first-page":"218","volume-title":"ECDEU Assessment Manual for Psychopharmacology\u2010Revised","author":"Guy W","year":"1976"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-022-02626-0"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010000"},{"key":"e_1_2_13_27_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.86.16_supplement.P1.164","article-title":"Understanding patient adherence to prophylactic migraine medications (P1.164)","volume":"86","author":"Vanya M","year":"2016","journal-title":"Neurology"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01366-9"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01368-7"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01212-4"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14196"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:33:11Z","timestamp":1762075991000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,21]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1111\/head.14606"],"URL":"https:\/\/doi.org\/10.1111\/head.14606","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,21]]},"assertion":[{"value":"2023-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}